9c46145e_nter___Yale_School_of_Medicine__Conditions
[Study Title] A PHASE I, OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF MOXR0916 ADMINISTERED INTRAVENOUSLY AS A SINGLE AGENT TO PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS [Conditions] 
Soft Tissue
M e l a n o m a , s k i n
S o f t T i s s u e
Mario Sznol, MD > Yale Cancer Center | Yale School of Medicine
Conditions